Phase III Trial of Dalcetrapib: Discontinued Due to Lack of Efficacy

By Sweetlove Mel  

Pharmaceutical Medicine, Vol. 26, Iss. 4, 2012-08 ,pp. : 253-256

Adis International

Access to resources Recommend Favorite

Current Phase II clinical data for ridaforolimus in cancer

By Spreafico Anna   Mackay Helen J  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1485-1493

Informa Healthcare

Access to resources Recommend Favorite

Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Phase I Study

By Derks Michael   Anzures-Cabrera Judith   Turnbull Lynn   Phelan Mary  

Clinical Drug Investigation, Vol. 31, Iss. 5, 2011-05 ,pp. : 325-335

Adis International

Access to resources Recommend Favorite

Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

By Lheureux Stephanie   Wilson Michelle   Mackay Helen J  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 773-792

Informa Healthcare

Access to resources Recommend Favorite

Phase II angiogenesis stimulators

By Ribatti Domenico  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 9, 2013-09 ,pp. : 1157-1166

Informa Healthcare

Access to resources Recommend Favorite